Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

  • 1.

    Bang, J., Spina, S. & Miller, B. L. Frontotemporal dementia. Lancet 386, 1672–1682 (2015).

  • 2.

    Coyle-Gilchrist, I. T. et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86, 1736–1743 (2016).

  • 3.

    Tsai, R. M. & Boxer, A. L. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J. Neurochem. 138, 211–221 (2016).

  • 4.

    Young, J. J. et al. Frontotemporal dementia: latest evidence and clinical implications. Ther. Adv. Psychopharmacol. 8, 33–48 (2018).

  • 5.

    Panza, F. et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73–88 (2019).

  • 6.

    Ihl, R. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J. Biol. Psychiatry 12, 2–32 (2011).

  • 7.

    Huey, E. D.,…

  • Read more…